FDA Approves GSK Hepatitis B Drug
The US FDA has approved GSK's Hibsago for chronic hepatitis B, marking the first antisense oligonucleotide for the liver infection. The treatment could allow patients to stop long-term therapy while keeping the virus suppressed, supporting the drugmaker's growth targets.
Xurve View
Insights:
Xurve View
The United States Food and Drug Administration approved GSK PLC-SPON ADR's hepatitis B drug Hibsago on Tuesday morning, allowing patients to keep the liver infection suppressed after stopping treatment. The approval marks the first antisense oligonucleotide authorized for chronic hepatitis B in the country. The treatment is central to the United Kingdom-based drugmaker's strategy to reach more than £40 billion in annual revenue by 2031.
